The global raltegravir market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Raltegravir comes under a class of medications called HIV integrase inhibitors. It binds and inhibits integrase, an HIV enzyme that inserts viral genetic material into the genetic material of the infected human cell. Treatment of HIV is one of the key application area of raltegravir; therefore considerable increase in the prevalence of HIV is one of the major factors driving demand for raltegravir market. According to the data published by World Health Organization in 2021, HIV is a global public health issue that claimed 37.3 million lives. Further, as per the same source, approximately 37.7 million were living with HIV at the end of 2020, out of which one-third of the people belong to the African region. Moreover, in 2020, 68,00,00 mortalities occurred due to HIV-related causes and 1.5 million people acquired HIV.
The high government intervention in form of government incentives, schemes, or funding is further promoting the growth of the global raltegravir market. For instance, in March 2021, Human Resources and Services Administration (HRSA) has awarded $99 million to expand access to HIV care, treatment, and support services under the “Ending the HIV Epidemic (EHE) “ scheme. Moreover, the EHE initiative aims to reduce HIV infections in the US by 90.0% by 2030 and new HIV infections to less than 3000 annually. In addition, Health and Human Services(HHS) have awarded $117 million intending to end the HIV infections in the US, out of which $60 million is dedicated to linking people with HIV who are newly diagnosed. Thus, such initiatives are anticipated to create demand for raltegravir which in turn will drive the global market growth during the forecast period.
In addition, the market is currently experiencing several product innovations and advancement. For instance, in September 2021, ViiV Healthcare announced the exclusive license agreement with Shionogi to develop S-365598, a third-generation HIV integrase inhibitor with the potential for long-acting dosing intervals. Under the terms of the agreement, ViiV will make an upfront capital of $21 million to Shionogi, a $16 million payment for the achievement of clinical development, and royalties on net sales.
Moreover, ViiV Healthcare and Shionogi intend to initiate the first time in human studies with S-365598 by 2023.In addition, in July 2020, GlaxoSmithKline Plc has announced the approval of rukobia from the Us Food and Drug Administration (FDA). The drug in combination with other antiretrovirals is indicated to treat HIV-1 infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection failing their current ARV regime due to resistance or intolerance.
In July 2021, Unitaid and Clinton Health Initiative, Inc has announced an agreement with Hetero. The agreement aimed to make darunavir coupled with ritonavir as an alternate therapy for HIV patients in low-income and middle-income countries. In June 2020, ViiV Healthcare has received US FDA approval for Tivicay (dolutegravir) tablets and Tivicay PD (dolutegravir) tablets to treat HIV-1 infection in pediatric patients atleast 4 weeks old and weighing at least 3kg in combination with other antiretroviral treatments.Thus, such approvals and collaborations are anticipated to accelerate the growth of the global raltegravir market during the forecast period.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Raltegravir Market at: https://orionmarketreports.com/request-sample/?id=92671&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Distribution channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Merck & Co., Hetero Healthcare Ltd., and GlaxoSmithKline Plc among others.
A full report Raltegravir Market of is available at: https://orionmarketreports.com/raltegravir-market/92671/
Global Raltegravir Market Report by Segment
By Type
- Tablets
- Oral Powder
By Distribution Channel
- Hospital
- Drug Store
- Others
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
